Navigation Links
Viral infections, including flu, could be inhibited by naturally occurring protein
Date:6/12/2014

PITTSBURGH, June 12, 2014 By boosting a protein that naturally exists in our cells, an international team of researchers led by the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, has found a potential way to enhance our ability to sense and inhibit viral infections.

The laboratory-based discovery, which could lead to more effective treatments for viruses ranging from hepatitis C to the flu, appears in the June 19 issue of the journal Immunity. The research is supported by the National Institutes of Health.

"Despite remarkable advances in vaccination and treatment, diseases caused by viral infections remain among the leading causes of death worldwide," said senior author Saumendra N. Sarkar, Ph.D., assistant professor of microbiology and molecular genetics at UPCI. "We need new defenses against viral infections, and our discovery is proving to be a promising avenue for further exploration."

Dr. Sarkar and his team made the discovery while investigating a protein called oligoadenylate synthetases-like, or OASL, which appears in increased quantities in people with liver cancer caused by the hepatitis C virus.

Hepatitis C, influenza, the childhood respiratory illness RSV, and many other viruses are known as ribonucleic acid (RNA) viruses, which use RNA as their genetic material when they replicate. The OASL protein enhances cells' ability to detect virus RNA, activating the immune system to sense the virus and inhibit replication.

In laboratory tests, boosting this protein in human cells effectively inhibits viral replication. Conversely, mice that do not have OASL were found to be much more susceptible to viral infections.

The finding is especially notable because it may offer an alternative to interferons, another kind of protein that is made and released by cells in response to viruses. Interferons are used in therapy against some viral infections, including hepatitis C, but are not effective for other RNA viruses, such as influenza. Interferon therapy also has major side effects, and not all patients respond well to treatment.

Dr. Sarkar and his team plan to determine the most efficient way to boost the OASL pathway in patients and are working with pulmonologists to develop and identify funding for a study to evaluate the effect of boosting OASL in people with lung infections.

"The respiratory system is a much easier target to deliver this type of therapy, compared to an organ, such as the liver, so we'll be starting with infections like RSV," said Dr. Sarkar. "From there we could branch out to other RNA viruses and perhaps find effective ways to boost our inherent immunity against a broad range of viral infections."


'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Antiviral therapy may prevent liver cancer in hepatitis B patients
2. Our own treacherous immune genes can cause cancer after viral infection
3. Hemorrhagic fevers can be caused by bodys antiviral interferon response
4. Going viral to target tumors
5. Could statins be used to fight a deadly viral infection?
6. Long distance signals protect brain from viral infections
7. Viral microRNAs responsible for causing AIDS-related cancer, new USC study shows
8. Does the bodys immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?
9. Population Council awarded USAID cooperative agreement to develop non-antiretroviral HIV microbicide
10. PDL-1 antibody could help immune system fight off influenza viral infection, study suggests
11. BU researchers explore possible link between cognitive depressive symptoms and antiretroviral therapy uptake
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is the first technology to directly address the resolution to globally reduce the ... is a patented compound of FDA and TTB approved ingredients that when infused ...
(Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... dedicated to advancing the science and clinical practice of radiosurgery, announced today ... Registry, a multi-institutional, observational registry established to standardize data collection from patients ...
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... WHO: ... Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak to ... written to President Trump in support of an independent vaccine safety commission. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, a ... a class action lawsuit on behalf of purchasers of ... ) pursuant and/or traceable to Kitov,s initial public offering ... on the open market from November 20, 2015 through ... The lawsuit seeks to recover damages for Kitov investors ...
(Date:3/28/2017)... , March 29, 2017 ... Siteless CRO platform, announced today study results ... Managed Care Pharmacy, #AMCP2017, Managed Care and Specialty Pharmacy ... . Data in both posters demonstrated that pharmacist-led ... and protocol adherence. These factors are crucial to generating ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology: